Treatment modifiers across different regimens of natalizumab treatment in MS: an Italian real-world experience

despite its widespread use in clinical practice, the effectiveness of natalizumab extended interval dosing (EID) adopted from treatment start across different treatment intervals and individual modifiers (body mass index BMI) is still under-investigated. here, seven-hundred and forty-five multiple sclerosis (MS) patients, exposed to natalizumab for 3.30 +/- 1.34 years, were retrospectively enrolled in an observational multicenter study. after stratifying patients in EID or standard interval dosing (SID), we assessed differences in time to relapse, MRI activity and expanded disability status scale (EDSS) progression. the primary analysis was conducted on patients exposed to EID interval from 5 weeks and 1 day to 7 weeks, while a secondary analysis included also EID periods up to 8 weeks. an additional analysis explored the impact of BMI. no differences in time to first relapse, time to radiological activity, time to EDSS progression or time to EDA (evidence of disease activity) were detected between SID and EID group (EID interval from 5 weeks to 1 day to 7 weeks). when including EID periods from 7 weeks and 1 day to 8 weeks, the EID group showed a trend towards higher risk of experience clinical relapses than the SID group. a higher EDA risk was also identified in EID patients with BMI above median. In conclusion, a higher risk of relapses seems to occur for EID above 7 weeks. Independently from the EID scheme adopted, higher BMI increases the risk of EDA in these patients.